LLY

1,177.42

+4.19%↑

JNJ

233.3

+0.28%↑

ABBV

225.86

-0.65%↓

UNH

402.18

+0.47%↑

MRK

121.76

+0.69%↑

LLY

1,177.42

+4.19%↑

JNJ

233.3

+0.28%↑

ABBV

225.86

-0.65%↓

UNH

402.18

+0.47%↑

MRK

121.76

+0.69%↑

LLY

1,177.42

+4.19%↑

JNJ

233.3

+0.28%↑

ABBV

225.86

-0.65%↓

UNH

402.18

+0.47%↑

MRK

121.76

+0.69%↑

LLY

1,177.42

+4.19%↑

JNJ

233.3

+0.28%↑

ABBV

225.86

-0.65%↓

UNH

402.18

+0.47%↑

MRK

121.76

+0.69%↑

LLY

1,177.42

+4.19%↑

JNJ

233.3

+0.28%↑

ABBV

225.86

-0.65%↓

UNH

402.18

+0.47%↑

MRK

121.76

+0.69%↑

Home・Aktien・Quanterix Corp

Quanterix Corp

Open

BrancheGesundheitswesen

3.25 -0.91

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.23

Max

3.34

Schlüsselkennzahlen
By Trading Economics
Einkommen	5.6M -18M
Verkäufe	-7.4M 36M
EPS	0.16
Gewinnspanne	-48.17
Angestellte	450
EBITDA	1.5M -15M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+21.21% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	6. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	6.3M 165M
Vorheriger Eröffnungskurs	4.16
Vorheriger Schlusskurs	3.25

Nachrichtenstimmung

By Acuity

50%

139 / 344 Ranking in Healthcare

Quanterix Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Quanterix Corp Prognose

Kursziel

By TipRanks

21.21% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 21.21%

Hoch 4 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Quanterix Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Quanterix Corp – Dist abgegeben haben.

Stimmung

By Acuity

139 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.